JP2018536383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536383A5 JP2018536383A5 JP2018512283A JP2018512283A JP2018536383A5 JP 2018536383 A5 JP2018536383 A5 JP 2018536383A5 JP 2018512283 A JP2018512283 A JP 2018512283A JP 2018512283 A JP2018512283 A JP 2018512283A JP 2018536383 A5 JP2018536383 A5 JP 2018536383A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- variant
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 55
- 238000000034 method Methods 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 210000001519 tissue Anatomy 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 230000005847 immunogenicity Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 238000003860 storage Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000011502 immune monitoring Methods 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021047883A JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047882A JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047884A JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237091P | 2015-10-05 | 2015-10-05 | |
| GBGB1517538.3A GB201517538D0 (en) | 2015-10-05 | 2015-10-05 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| US62/237,091 | 2015-10-05 | ||
| GB1517538.3 | 2015-10-05 | ||
| PCT/EP2016/073416 WO2017060169A1 (en) | 2015-10-05 | 2016-09-30 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047882A Division JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047883A Division JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047884A Division JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536383A JP2018536383A (ja) | 2018-12-13 |
| JP2018536383A5 true JP2018536383A5 (OSRAM) | 2019-06-13 |
| JP6868010B2 JP6868010B2 (ja) | 2021-05-12 |
Family
ID=54606079
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512283A Active JP6868010B2 (ja) | 2015-10-05 | 2016-09-30 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047884A Active JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047882A Active JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047883A Active JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047884A Active JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047882A Active JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047883A Active JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US10253077B2 (OSRAM) |
| EP (1) | EP3359560A1 (OSRAM) |
| JP (4) | JP6868010B2 (OSRAM) |
| KR (1) | KR20180055826A (OSRAM) |
| CN (1) | CN108699119A (OSRAM) |
| AU (3) | AU2016335177B2 (OSRAM) |
| CA (1) | CA3001074A1 (OSRAM) |
| CL (1) | CL2018000780A1 (OSRAM) |
| CO (1) | CO2018003659A2 (OSRAM) |
| CR (3) | CR20180191A (OSRAM) |
| EA (1) | EA201890635A1 (OSRAM) |
| GB (1) | GB201517538D0 (OSRAM) |
| MA (2) | MA45424A (OSRAM) |
| MX (1) | MX2018004140A (OSRAM) |
| PE (1) | PE20181799A1 (OSRAM) |
| SG (2) | SG10202003124TA (OSRAM) |
| TW (1) | TWI776245B (OSRAM) |
| WO (1) | WO2017060169A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY198087A (en) * | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| CN119080881A (zh) | 2017-07-07 | 2024-12-06 | 伊玛提克斯生物技术有限公司 | 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物 |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| EP3668893A4 (en) * | 2017-08-16 | 2021-08-04 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2019204576A1 (en) * | 2018-04-19 | 2019-10-24 | The University Of Chicago | Methods and kits for diagnosis and triage of patients with colorectal liver metastases |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| CN109485721A (zh) * | 2018-11-23 | 2019-03-19 | 杜学明 | 一种获得肿瘤特异性t细胞受体的方法 |
| EP3894561A4 (en) * | 2018-12-11 | 2022-12-14 | The Brigham and Women's Hospital, Inc. | CANCER TREATMENT METHODS |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| EP3739588A1 (en) * | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| CN110398584B (zh) * | 2019-05-23 | 2023-01-24 | 广东药科大学 | 血清Slit2作为结直肠癌诊治和转移监测标志物的应用 |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| WO2020257922A1 (en) * | 2019-06-25 | 2020-12-30 | Université de Montréal | Novel tumor-specific antigens for ovarian cancer and uses thereof |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| EP4196586A1 (en) | 2020-10-08 | 2023-06-21 | Albert-Ludwigs-Universität Freiburg | Casp8ap2 antagonists for use in the prevention or treatment of cancer |
| US20240024439A1 (en) * | 2020-12-07 | 2024-01-25 | Iogenetics, Llc | Administration of anti-tumor vaccines |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| US20250235517A1 (en) * | 2022-03-30 | 2025-07-24 | Iogenetics, Llc | Tumor-associated antigens in brain tumors |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN117384859B (zh) * | 2023-12-13 | 2024-03-22 | 北京翊博生物集团有限公司 | 一种树突状细胞来源的外泌体的制备方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20060045881A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| EP2502628B1 (en) * | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| TWI538685B (zh) * | 2010-04-02 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｅｃｔ２胜肽及含此胜肽之疫苗 |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CA2826186C (en) * | 2011-02-01 | 2020-08-04 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
| US20120302503A1 (en) * | 2011-05-23 | 2012-11-29 | AML Therapeutics, LLC | PEPTIDES FOR PREVENTING OR TREATING A DISEASE OR DISORDER ASSOCIATED WITH CBP OR p300 MISREGULATION, AND METHODS FOR USE AND IDENTIFICATION THEREOF |
| TWI819228B (zh) | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
-
2015
- 2015-10-05 GB GBGB1517538.3A patent/GB201517538D0/en not_active Ceased
-
2016
- 2016-09-30 CN CN201680057635.2A patent/CN108699119A/zh active Pending
- 2016-09-30 US US15/281,537 patent/US10253077B2/en active Active
- 2016-09-30 CR CR20180191A patent/CR20180191A/es unknown
- 2016-09-30 MX MX2018004140A patent/MX2018004140A/es unknown
- 2016-09-30 JP JP2018512283A patent/JP6868010B2/ja active Active
- 2016-09-30 WO PCT/EP2016/073416 patent/WO2017060169A1/en not_active Ceased
- 2016-09-30 EA EA201890635A patent/EA201890635A1/ru unknown
- 2016-09-30 EP EP16774689.0A patent/EP3359560A1/en active Pending
- 2016-09-30 CR CR20200516A patent/CR20200516A/es unknown
- 2016-09-30 SG SG10202003124TA patent/SG10202003124TA/en unknown
- 2016-09-30 MA MA045424A patent/MA45424A/fr unknown
- 2016-09-30 CR CR20200515A patent/CR20200515A/es unknown
- 2016-09-30 AU AU2016335177A patent/AU2016335177B2/en not_active Ceased
- 2016-09-30 PE PE2018000322A patent/PE20181799A1/es unknown
- 2016-09-30 KR KR1020187007972A patent/KR20180055826A/ko not_active Ceased
- 2016-09-30 CA CA3001074A patent/CA3001074A1/en active Pending
- 2016-09-30 SG SG11201801344SA patent/SG11201801344SA/en unknown
- 2016-09-30 MA MA42021A patent/MA42021A1/fr unknown
- 2016-10-05 TW TW109133819A patent/TWI776245B/zh not_active IP Right Cessation
-
2018
- 2018-03-26 CL CL2018000780A patent/CL2018000780A1/es unknown
- 2018-04-05 CO CONC2018/0003659A patent/CO2018003659A2/es unknown
- 2018-12-27 US US16/233,284 patent/US10377802B2/en active Active
- 2018-12-31 US US16/237,284 patent/US10597432B2/en active Active
- 2018-12-31 US US16/237,279 patent/US10487126B2/en active Active
-
2019
- 2019-10-02 US US16/591,323 patent/US10654904B2/en not_active Expired - Fee Related
-
2021
- 2021-02-19 AU AU2021201108A patent/AU2021201108A1/en not_active Abandoned
- 2021-02-19 AU AU2021201107A patent/AU2021201107A1/en not_active Abandoned
- 2021-03-22 JP JP2021047884A patent/JP7344919B2/ja active Active
- 2021-03-22 JP JP2021047882A patent/JP7344917B2/ja active Active
- 2021-03-22 JP JP2021047883A patent/JP7344918B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536383A5 (OSRAM) | ||
| JP2018520653A5 (OSRAM) | ||
| JP2018521641A5 (OSRAM) | ||
| JP2019510465A5 (OSRAM) | ||
| JP2019502360A5 (OSRAM) | ||
| JP2018518956A5 (OSRAM) | ||
| JP2018510628A5 (OSRAM) | ||
| JP2021168652A5 (OSRAM) | ||
| JP2018511321A5 (OSRAM) | ||
| JP2018529320A5 (OSRAM) | ||
| JP2018518937A5 (OSRAM) | ||
| JP2018509135A5 (OSRAM) | ||
| JP2018519243A5 (OSRAM) | ||
| JP2019506838A5 (OSRAM) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2019511214A5 (OSRAM) | ||
| JP2017525336A5 (OSRAM) | ||
| JP2018519825A5 (OSRAM) | ||
| JP2024099580A5 (OSRAM) | ||
| JP2017502076A5 (OSRAM) | ||
| AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| US9056069B2 (en) | Cancer therapy based on tumor associated antigens derived from cyclin D1 | |
| JP2017524337A5 (OSRAM) | ||
| JP2020530759A5 (OSRAM) | ||
| JP2018520644A5 (OSRAM) |